Moreover, troglitazone derivativeswhich are unable to activate PPARγ suppress cancer cell proliferationsimilar to troglitazone, giving further evidence that the antiproliferativeeffects of troglitazone are at least in part PPARγ-independent [61]. This evidence concerns the gene PPARG and cancer.